ライフサイエンスコーパス: gallbladder cancer

1 cinoma vs extrahepatic cholangiocarcinoma vs gallbladder cancer).

2 es to identify miR-125b-5p down-regulated in gallbladder cancer.

3 observed for pancreatic cancer and liver and gallbladder cancer.

4 ent for localized or locoregionally advanced gallbladder cancer.

5 alone among previously treated patients with gallbladder cancer.

6 therapy should be considered in treatment of gallbladder cancer.

7 e early diagnosis and effective treatment of gallbladder cancer.

8 select patients with incidentally discovered gallbladder cancer.

9 fy common genetic susceptibility alleles for gallbladder cancer.

10 olipid transporter genes in the pathology of gallbladder cancer.

11 hich mediates the function of miR-125b-5p in gallbladder cancer.

12 of Bcl2 is correlated with poor prognosis in gallbladder cancer.

13 chemoradiotherapy for patients with resected gallbladder cancer.

14 , whereas VEGF variants were associated with gallbladder cancer.

15 zes advances in understanding the biology of gallbladder cancer.

16 herapeutic agents for the treatment of human gallbladder cancer.

17 ct of rapamycin as a potential treatment for gallbladder cancer.

18 aggressive wide resection for bile duct and gallbladder cancer.

19 l cholelithiasis, chronic cholecystitis, and gallbladder cancer.

20 play a causative role in the development of gallbladder cancer.

21 ents with extrahepatic cholangiocarcinoma or gallbladder cancer.

22 endometrial, 46% in urothelial, and 45.5% of gallbladder cancers.

23 was low in patients with surgically resected gallbladder cancers.

24 considered in the differential diagnosis of gallbladder cancers.

25 ted with increased survival in node-positive gallbladder cancers.

26 Of 449 patients with gallbladder cancer, 207 cases (46%) were discovered inci

27 atients who underwent definitive surgery for gallbladder cancer, 4559 were women (71.3%); median age

28 ary cancer (cholangiocarcinoma) (63 months), gallbladder cancer (47 months), metastatic colorectal ca

29 ield of laparoscopy was 48% in patients with gallbladder cancer (56% in those who did not undergo pre

30 Joint Committee on Cancer (AJCC) staging for gallbladder cancer (6th Edition) involved some major cha

31 A majority of patients had gallbladder cancer (80%).

32 lence of seropositivity was higher: 100% for gallbladder cancer, 97% of extrahepatic bile duct cancer

33 ntributed to the biochemical epidemiology of gallbladder cancer, a case-control study was undertaken

34 Records of 107 patients with gallbladder cancer admitted to a tertiary academic medic

35 f reoperation after an incidental finding of gallbladder cancer after cholecystectomy, and results of

36 firmed cholangiocarcinoma or muscle-invasive gallbladder cancer after resection with curative intent

37 survival in various BTC subtypes, including gallbladder cancer, ampulla of Vater cancer, and cholang

38 llow-up of 5.3 years), 206 (0.03%) developed gallbladder cancer and 265 (0.04%) extrahepatic and 131

39 ents with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgic

40 y of mass or abdominal paracentesis, showing gallbladder cancer and adenocarcinoma.

41 as altered the presentation of patients with gallbladder cancer and determine whether radical resecti

42 ese imaging studies also serve to screen for gallbladder cancer and HCC.

43 ccuracy of laparoscopy between patients with gallbladder cancer and hilar cholangiocarcinoma.

44 Of these, three patients with gallbladder cancer and one patient with cholangiocarcino

45 patients with potentially resectable primary gallbladder cancer and patients with T2/T3 hilar cholang

46 IV stricture, biliary obstruction caused by gallbladder cancer and when only partial liver drainage

47 oma (iCCA), extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer, exhibit poor p

48 ated with a survival advantage in resectable gallbladder cancer, and neoadjuvant chemotherapy was ass

49 for re-resection for incidentally discovered gallbladder cancer appears to be between 4 and 8 weeks a

50 ar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in mo

51 Although gallstones are recognized causes of gallbladder cancer, associations with other cancers of t

52 e-exploration after an incidental finding of gallbladder cancer at initial cholecystectomy.

53 underwent definitive surgical resection for gallbladder cancers between January 1, 2004, and January

54 ded for continued use in pancreatic head and gallbladder cancers but not in ampullary malignancies.

55 explored at a later point when found to have gallbladder cancer by subsequent pathology (n = 33).

56 The discovery cohort comprised 1042 gallbladder cancer cases and 1709 controls and the repli

57 ols and the replication cohort contained 428 gallbladder cancer cases and 420 controls.

58 n study (GWAS), we did a genome-wide scan of gallbladder cancer cases and hospital visitor controls,

59 125b-5p up-regulation promoted cell death in gallbladder cancer cells in the presence of cisplatin.

60 ockdown of miR-125b-5p reduced cell death in gallbladder cancer cells treated with cisplatin.

61 by data, an analysis of the 10,705 cases of gallbladder cancer collected between 1989 and 1996 in th

62 rget of rapamycin (mTOR; Ser(2448)) in human gallbladder cancer compared with normal gallbladder tiss

63 Although the OR for gallbladder cancer could not be calculated, the OR for t

64 ue to iCCA increased by 120.0%, those due to gallbladder cancer decreased by 45.5%, and those due to

65 using data from 4,180 patients with resected gallbladder cancer diagnosed from 1988 to 2003 from the

66 years with microscopically confirmed primary gallbladder cancer diagnosed or treated at Tata Memorial

67 In conclusion, cases with gallbladder cancer differed from controls with stones an

68 Gallbladder cancer (GBC) has a female predominance, wher

69 esistance and compromised early diagnosis of gallbladder cancer (GBC) has led to poor patient prognos

70 Gallbladder cancer (GBC) is a highly aggressive malignan

71 Gallbladder cancer (GBC) is a highly fatal cancer that c

72 Gallbladder cancer (GBC) is an aggressive gastrointestin

73 ausal association of gallbladder stones with gallbladder cancer (GBC) is not yet well established.

74 Gallbladder cancer (GBC) is rare, but lethal.

75 Gallbladder cancer (GBC) is the most common cancer of th

76 ically significantly lower incidence rate of gallbladder cancer (GBC) relative to tea nondrinkers (HR

77 that KPNA2 was significantly upregulated in gallbladder cancer (GBC), and the increased levels were

78 estigated the frequency of DNA repair GAs in gallbladder cancer (GBC), association with tumor mutatio

79 tiation 14 (sCD14) have been associated with gallbladder cancer (GBC), but the association with sCD14

80 percent of the Indian population suffer from gallbladder cancer (GBC).

81 metastases on outcome after R0 resection of gallbladder cancer (GBCA).

82 nd low pass whole genomes (n = 146) from 167 gallbladder cancers (GBCs) from patients in Korea, India

83 t chemotherapy chemoradiotherapy in resected gallbladder cancers (GBCs).

84 Chile has high incidence rates of gallbladder cancer globally, particularly among Amerindi

85 Gallbladder cancer had been diagnosed preoperatively by

86 increased risk of cholangiocarcinoma (CCA), gallbladder cancer, hepatocellular carcinoma (HCC), and

87 d extended/radical cholecystectomy for T2/T3 gallbladder cancer; however, many tumors are discovered

88 ture (HR 2.082, P=0.008), obstruction due to gallbladder cancer (HR 31.029, P=0.012) and only partial

89 isk reduction in 10 of 13 OACs, including in gallbladder cancer (HR, 0.35; 95% CI, 0.15-0.83), mening

90 R, 21.00), pancreatic cancer (HR, 5.26), and gallbladder cancer (HR, 9.19) (P < .001 for all).

91 ts with localized or locoregionally advanced gallbladder cancers (ie, categories cTx-cT4, cN0-2, and

92 Preoperative predictors of incidental gallbladder cancer (iGBC) have been poorly defined despi

93 rial of CAPIRI vs IRI alone for treatment of gallbladder cancer in patients who had disease progressi

94 to have resulted in the earlier discovery of gallbladder cancer in some patients, resulting in increa

95 perihilar and distal cholangiocarcinomas and gallbladder cancers in Japanese patients.

96 so substantially influenced the treatment of gallbladder cancer; in other tumor types, results were i

97 to an open resection when identified to have gallbladder cancer intraoperatively (n = 6) and those wh

98 copic cholecystectomy and were found to have gallbladder cancer intraoperatively or following the ope

99 Unresected gallbladder cancer is a rapidly fatal disease.

100 e whether radical resection in patients with gallbladder cancer is beneficial.

101 The surgical management of gallbladder cancer is controversial.

102 Gallbladder cancer is highly lethal, with notable differ

103 studies have shown that the overall risk of gallbladder cancer is not increased in patients with sma

104 Gallbladder cancer is uncommon but highly fatal.

105 vant and adjuvant chemotherapy in resectable gallbladder cancer is unknown.

106 ough adjuvant chemoradiotherapy for resected gallbladder cancer may improve survival for some patient

107 01, 100 patients with potentially resectable gallbladder cancer (n = 44) and hilar cholangiocarcinoma

108 ant epithelioid hemangioendothelioma: n = 1, gallbladder cancer: n = 1 or metastatic disease [colorec

109 However, in patients with node-positive gallbladder cancer, neoadjuvant therapy was associated w

110 sm has traditionally surrounded treatment of gallbladder cancer, particularly since the majority of c

111 s in the optimum management of patients with gallbladder cancer, particularly with respect to the pot

112 the net survival benefit of adjuvant RT for gallbladder cancer patients based on specific tumor and

113 tion as a new biomarker for the prognosis of gallbladder cancer patients.

114 -C30) and the 21-item Cholangiocarcinoma and Gallbladder Cancer Quality of Life Module (QLQ-BIL21).

115 t the Akt/mTOR pathway is activated in human gallbladder cancer, rapamycin and related drugs may be e

116 he benefit of adjuvant radiotherapy (RT) for gallbladder cancer remains controversial because most pu

117 Gallbladder cancer represents the most common malignancy

118 ement from the addition of adjuvant RT after gallbladder cancer resection.

119 eport of common genetic variation conferring gallbladder cancer risk at genome-wide significance.

120 ciated with substantial variation in risk of gallbladder cancer (sibling relative risk 3.15 [95% CI 1

121 incidence, 373 per 10 000 person-years) and gallbladder cancer (SMR, 3.82 [95% CI, 3.31-4.39]; morta

122 review of 149 patients with the diagnosis of gallbladder cancer treated from 1985 to 1993 was perform

123 Gallbladder cancer was found incidentally in 53 patients

124 ith newly diagnosed histologically confirmed gallbladder cancer were compared with 264 controls with

125 ion (1987-2007) were analyzed; patients with gallbladder cancer were excluded.

126 vs those taking metformin for colorectal and gallbladder cancer were less than 1, but the risk reduct

127 Patients with resected gallbladder cancer were selected from the Surveillance,

128 esection for metastatic colorectal cancer or gallbladder cancer were usually considered cured.

129 l samples, miR-125b-5p was down-regulated in gallbladder cancer whereas Bcl2 was up-regulated and the

130 emotherapy in the treatment of patients with gallbladder cancer who experience disease progression af

131 firmed cholangiocarcinoma or muscle-invasive gallbladder cancer who had undergone a macroscopically c

132 of 207 patients with incidentally discovered gallbladder cancer who underwent reoperation and had ava